A new drug combo of enzalutamide and hormone therapy has been shown to extend survival for men with recurring prostate cancer, reducing death risk by over 40%. The study followed more than 1,000 ...
Screening for prostate cancer becomes more complex in men over the age of 70. The US Preventive Services Task Force (USPSTF) currently recommends against routine PSA testing in this age group. The PSA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results